Methylprednisolone
Methylprednisolone
Medrol (oral), Solu-Medrol (IV/IM), Depo-Medrol (depot injection)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Autoimmune disease flare0, Asthma/COPD exacerbation (IV in severe disease)0, Multiple sclerosis relapse (high-dose IV pulse)0, Transplant rejection0, Intra-articular for arthritis (Depo-Medrol)0
Pharmacy
Starting dose
PO Medrol Dosepak (5-day taper from 24 mg to 4 mg) is the prototypic short-course outpatient regimen; IV pulse 1 g daily for 3-5 days for MS relapse; intra-articular 4-80 mg per joint q1-5 weeks
Preparations
2, 4, 8, 16, 32 mg oral tablets; 40, 125, 500, 1000 mg IV vials; Depo-Medrol 20, 40, 80 mg/mL IM depot
US FDA Max
Indication-specific
Pharmacology
Routes
Oral, IM, IV, intra-articular, intrathecal (rare and controversial)
Onset
IV pulse: hours; PO: hours; intra-articular: days
Duration
Biologic 12-36 hours (intermediate-acting); Depo-Medrol depot weeks
Half-life
Plasma 2-3 hours; biologic ~18-36 hours[1]
Bioavailability
~80-99% (oral)[1]
Pregnancy
Use when benefits outweigh; small association with oral clefts in first trimester debated.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Methylprednisolone is a synthetic glucocorticoid agonist intermediate in potency between prednisone/prednisolone and dexamethasone, with negligible mineralocorticoid activity (less sodium/water retention than hydrocortisone).0 Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. Unlike prednisone, it does not require hepatic activation, making it the preferred oral choice in severe hepatic dysfunction[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Medrol (methylprednisolone), Pfizer/Pharmacia, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011153s080lbl.pdf